Literature DB >> 16533748

Cytotoxic chemotherapy successfully induces durable complete remission in 2 patients with mosquito allergy resulting from Epstein-Barr virus-associated T-/natural killer cell lymphoproliferative disease.

M Koyama1, Y Takeshita, A Sakata, A Sawada, M Yasui, T Okamura, M Inoue, K Kawa.   

Abstract

Recent findings indicate that Epstein-Barr virus (EBV)-infected T-/natural killer (NK) cells play an important role in the pathogenesis of mosquito allergy, and most patients with mosquito allergy die early in life if not properly treated. Over the last 7 years, we have been using combination chemotherapy and allogeneic stem cell transplantation for the treatment of EBV-associated T-/NK cell lymphoproliferative disease (LPD) in which chronic active EBV infection and mosquito allergy were included. As of this writing, we have successfully treated 2 patients with mosquito allergy with chemotherapy in which EBV-infected T-/NK cells were eradicated. The findings suggest the possible role of chemotherapy in the treatment of EBV-associated T-/NK cell LPD.

Entities:  

Mesh:

Year:  2005        PMID: 16533748     DOI: 10.1532/IJH97.05083

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  10 in total

1.  Mosquito allergy and Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease.

Authors:  K Kawa; T Okamura; K Yagi; M Takeuchi; M Nakayama; M Inoue
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

2.  Clinical and virologic characteristics of chronic active Epstein-Barr virus infection.

Authors:  H Kimura; Y Hoshino; H Kanegane; I Tsuge; T Okamura; K Kawa; T Morishima
Journal:  Blood       Date:  2001-07-15       Impact factor: 22.113

3.  Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease.

Authors:  T Okamura; T Kishimoto; M Inoue; M Honda; N Yamashita; H Wakiguchi; M Yagita; G Hosoi; M Sako; M Yasui; K Yagi; K Kawa
Journal:  Bone Marrow Transplant       Date:  2003-01       Impact factor: 5.483

4.  Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation.

Authors:  T Okamura; Y Hatsukawa; H Arai; M Inoue; K Kawa
Journal:  Lancet       Date:  2000-07-15       Impact factor: 79.321

5.  Chronic active Epstein-Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation.

Authors:  T Taketani; A Kikuchi; J Inatomi; R Hanada; H Kawaguchi; K Ida; T Oh-Ishi; T Arai; H Kishimoto; K Yamamoto
Journal:  Bone Marrow Transplant       Date:  2002-03       Impact factor: 5.483

6.  CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA.

Authors:  K Kawa-Ha; S Ishihara; T Ninomiya; K Yumura-Yagi; J Hara; F Murayama; A Tawa; K Hirai
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

7.  CD4+ T-lymphocyte-induced Epstein-Barr virus reactivation in a patient with severe hypersensitivity to mosquito bites and Epstein-Barr virus-infected NK cell lymphocytosis.

Authors:  Hideo Asada; Sachiko Miyagawa; Yasuyuki Sumikawa; Yuji Yamaguchi; Satoshi Itami; Setsuo Suguri; Masakazu Harada; Yoshiki Tokura; Shigehiko Ishihara; Shiro Ohshima; Kunihiko Yoshikawa
Journal:  Arch Dermatol       Date:  2003-12

Review 8.  Diagnosis and treatment of Epstein-Barr virus-associated natural killer cell lymphoproliferative disease.

Authors:  Keisei Kawa
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

9.  Chronic active Epstein-Barr virus infection in children in Japan.

Authors:  S Ishihara; S Okada; H Wakiguchi; T Kurashige; T Morishima; K Kawa-Ha
Journal:  Acta Paediatr       Date:  1995-11       Impact factor: 2.299

10.  Hypersensitivity to mosquito bites conceals clonal lymphoproliferation of Epstein-Barr viral DNA-positive natural killer cells.

Authors:  S Ishihara; K Ohshima; Y Tokura; R Yabuta; H Imaishi; H Wakiguchi; T Kurashige; H Kishimoto; I Katayama; S Okada; K Kawa-Ha
Journal:  Jpn J Cancer Res       Date:  1997-01
  10 in total
  6 in total

1.  Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis.

Authors:  Ayako Arai; Ken-Ichi Imadome; Yuko Watanabe; Mayumi Yoshimori; Takatoshi Koyama; Takeharu Kawaguchi; Chiaki Nakaseko; Shigeyoshi Fujiwara; Osamu Miura
Journal:  Int J Hematol       Date:  2011-04-14       Impact factor: 2.490

Review 2.  How we treat chronic active Epstein-Barr virus infection.

Authors:  Akihisa Sawada; Masami Inoue; Keisei Kawa
Journal:  Int J Hematol       Date:  2017-02-16       Impact factor: 2.490

3.  Sequential monitoring of serum IL-6, TNF-α, and IFN-γ levels in a CAEBV patient treated by plasma exchange and immunochemotherapy.

Authors:  Ayako Arai; Ayako Nogami; Ken-Ichi Imadome; Morito Kurata; Naomi Murakami; Shigeyoshi Fujiwara; Osamu Miura
Journal:  Int J Hematol       Date:  2012-09-16       Impact factor: 2.490

Review 4.  Hematopoietic Stem Cell Transplantation for the Treatment of Epstein-Barr Virus-Associated T- or NK-Cell Lymphoproliferative Diseases and Associated Disorders.

Authors:  Akihisa Sawada; Masami Inoue
Journal:  Front Pediatr       Date:  2018-11-06       Impact factor: 3.418

5.  Severe degenerative change of multiple organs mediated by chronic active Epstein-Barr virus infection with infected T-cell expansion.

Authors:  Michihide Tokuhira; Atsushi Iizuka; Reiko Watanabe; Naoya Sekiguchi; Norihide Sato; Chen-Kang Chien; Yasunobu Sekiguchi; Tomoe Nemoto; Kyoko Hanzawa; Jun-Ichi Tamaru; Shinji Itoyama; Hiroshi Suzuki; Tsutomu Takeuchi; Shigehisa Mori; Masahiro Kizaki
Journal:  Int J Hematol       Date:  2008-04-23       Impact factor: 2.319

6.  P-glycoprotein is expressed and causes resistance to chemotherapy in EBV-positive T-cell lymphoproliferative diseases.

Authors:  Mayumi Yoshimori; Honami Takada; Ken-Ichi Imadome; Morito Kurata; Kouhei Yamamoto; Takatoshi Koyama; Norio Shimizu; Shigeyoshi Fujiwara; Osamu Miura; Ayako Arai
Journal:  Cancer Med       Date:  2015-07-08       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.